Allogene Therapeutics, Inc. (ALLO) vs 908 Devices Inc. (MASS)
A side-by-side comparison of Allogene Therapeutics, Inc. and 908 Devices Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALLO
Allogene Therapeutics, Inc.
$1.45HealthcareDelayed quote: Oct 6, 2026, 10:25 AM EDT
MASS
908 Devices Inc.
$12.51HealthcareDelayed quote: Oct 6, 2026, 10:25 AM EDT
Total return — ALLO vs MASS
growth of $100 · dividends reinvested · last 6yALLO -94.5% (-38.3%/yr)MASS -73.9% (-20.0%/yr)MASS compounded faster over this window
ALLO MASS
ALLO vs MASS: by the numbers
- •MASS is the larger company ($513M vs $499M market cap).
- •Both run net losses; MASS's is the smaller (-56.68% vs -3566.68% net margin).
- •MASS grew revenue faster over the past five years (18.92% vs -34.47% CAGR).
Metrics side by side
Valuation
| Metric | ALLO | MASS |
|---|---|---|
| P/S ratio | 107.49 | 8.44 |
| P/B ratio | 1.14 | 4.05 |
| FCF yield | N/A | 0.09% |
Profitability
| Metric | ALLO | MASS |
|---|---|---|
| Gross margin | 0.00% | 49.79% |
| Operating margin | 0.00% | -46.01% |
| Net margin | -3566.68% | -56.68% |
| ROE | -37.94% | -27.20% |
| ROIC | -34.79% | -18.90% |
Growth (annualized)
| Metric | ALLO | MASS |
|---|---|---|
| Revenue CAGR (5Y) | -34.47% | 18.92% |
| Total return CAGR (5Y) | -42.72% | -17.66% |
Frequently asked
- Which has grown faster, ALLO or MASS?
- Over the past five years, MASS grew revenue faster — ALLO at a -34.47% CAGR versus MASS at 18.92%.
- How have ALLO and MASS total returns compared?
- Over the past 5 years, ALLO delivered -42.72% and MASS delivered -17.66% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Allogene Therapeutics ROE908 Devices ROEAllogene Therapeutics operating margin908 Devices operating marginAllogene Therapeutics revenue growth908 Devices revenue growthAllogene Therapeutics free cash flow908 Devices free cash flow
Allogene Therapeutics & 908 Devices appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.